and in ascending order for each dose-effect curve. THC was administered intraperitoneally (i.p., Experiment 1) or subcutaneously (s.c., Experiment 2) 30 min prior to the test session. In Experiment 1, anandamide (0.1–10 mg/kg) and 2-AG (0.1–30 mg/kg) were administered i.p. 10 min prior to test sessions. In Experiment 2, anandamide (1–10 mg/kg) was administered s.c. 30 min before the start of the session. URB597 (0.3 mg/kg) and NAM (1 mg/kg) were injected i.p. 50 min before administration of anandamide (0.1–1 mg/kg) or 2-AG (0.1–1 mg/kg), respectively. Previous work has shown that these doses of URB597 and NAM enhanced the cannabimimetic effects of anandamide and 2-AG, respectively, but did not exhibit in vivo cannabimimetic activity when administered alone (Burston et al., 2008; Solinas et al., 2007). PF3845 (1–10 mg/kg) and JZL184 (3–30 mg/kg) were injected i.p. 120 min before the start of the session.
